← All trials
NCT06384352
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2024
- Primary completion
- Apr 7, 2027
- Completion date
- Apr 7, 2029
- First posted
- Apr 25, 2024
- Last posted
- Oct 15, 2024
- Enrollment
- 155
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Suzhou Medilink Therapeutics Ltd.Lead sponsor
- RocheCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.